# VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

> **NCT03556228** · PHASE1,PHASE2 · RECRUITING · sponsor: **VM Oncology, LLC** · enrollment: 242 (estimated)

## Conditions studied

- Head and Neck Carcinoma
- Adenoid Cystic Carcinoma
- Lung Cancer
- Non-Small Cell Lung Cancer
- Pancreatic Cancer
- Mesothelioma
- Esophageal Cancer
- Any Solid Tumors Progressed After a Prior Immunotherapy
- Head and Neck Squamous Cell Carcinoma
- Head and Neck Squamous Cell Carcinoma HNSCC
- Salivary Gland Carcinomas
- Head and Neck Cancers - Salivary Gland
- Head and Neck Cancers - Nasopharyngeal
- Head and Neck Cancers - Throat
- Small Cell Lung Cancer ( SCLC )
- Lung Cancer (Locally Advanced or Metastatic)
- Head and Neck Cancers - Tonsils
- Head and Neck Cancers Hypopharynx
- Head and Neck Cancers Larynx
- Head and Neck Cancers Lip
- Head and Neck Cancers Nasopharynx
- Head and Neck Cancers Oral Cavity
- Head and Neck Cancers
- Head and Neck Cancers Oropharynx
- Head and Neck Cancers Trachea

## Interventions

- **DRUG:** VMD-928 100 mg Tablet
- **DRUG:** VMD-928 Tablet and Pembrolizumab (200 mg)

## Key facts

- **NCT ID:** NCT03556228
- **Lead sponsor:** VM Oncology, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-06-08
- **Primary completion:** 2027-12
- **Final completion:** 2028-06
- **Target enrollment:** 242 (ESTIMATED)
- **Last updated:** 2025-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03556228

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03556228, "VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03556228. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*